The article you requested is

Reply to "Cardiopulmonary Complications of Ergot-Derivative Dopamine Agonists"

J Clin Psychiatry 2004;65(10):1430[letter]

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Rack et al. commented on our study of the treatment of risperidone-induced hyperprolactinemia with low doses of cabergoline with a warning about possible dangers of cardiopulmonary complications of ergot-derivative dopamine agonists. These adverse events are not yet completely understood, as only unconfirmed hypotheses (not driven by anatomicopathologicfindings) about possible serotonergic mechanisms linking ergoline dopamine agonist drugs to cardiopulmonary (fibrotic) findings have been made.1